S-SK609

S-SK609 is a G-protein biased signaling agonist of the dopamine D3 receptor (D3R) and an inhibitor of the norepinephrine transporter (NET). It is the active S-enantiomer of the racemic compound SK609. Developed by Drexel University and licensed to PolyCore Therapeutics, S-SK609 is designed to treat motor symptoms and levodopa-induced dyskinesia (LID) in Parkinson's disease, as well as cognitive impairment. Unlike traditional dopamine agonists, S-SK609 selectively activates D3R without recruiting beta-arrestin-2, thereby avoiding receptor desensitization, tolerance, and dyskinesia. Additionally, its selective inhibition of NET increases dopamine and norepinephrine levels in the prefrontal cortex, promoting cognitive enhancement without the psychostimulant-like side effects associated with dopamine transporter (DAT) inhibition.

Other names

ES609ES-609ES 609S-SK-609S-SK609S-SK 609S-SK609 HClS-SK-609 HClS-SK 609 HClS-SK609 hydrochlorideS-SK-609 hydrochlorideS-SK 609 hydrochlorideSK609SK-609SK 609SK609 HClSK-609 HClSK 609 HClSK609 hydrochlorideSK-609 hydrochlorideSK 609 hydrochloride